Trump announces trade deal with EU following months of negotiations
Twist Bioscience Corp (NASDAQ:TWST) recently disclosed that Paula Green, the Senior Vice President of Human Resources, sold a portion of her holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Green sold 918 shares of common stock on March 6, 2025, at an average price of $40.913 per share. The total transaction amounted to $37,558. The stock, which InvestingPro data shows has been quite volatile with a beta of 2.15, currently trades at $36.71, representing a decline of about 10% from the transaction price.
This sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs), as mandated by the company’s equity incentive plans. Following this transaction, Green retains ownership of 130,912 shares in Twist Bioscience. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 4.96, though it currently appears fairly valued based on comprehensive Fair Value calculations. InvestingPro subscribers have access to over 20 additional key metrics and insights for TWST, including detailed financial health scores and exclusive analyst revisions.
In other recent news, Twist Bioscience Corporation reported financial results for the first quarter of fiscal year 2025 that surpassed consensus predictions and previously issued company guidance. The company revised its full-year fiscal 2025 guidance, projecting total revenue growth of 19-21% year-over-year and gross margins expected to be around 49% for the full year. Additionally, Twist Bioscience anticipates an improved adjusted EBITDA loss of about $36 million. Following these results, Scotiabank (TSX:BNS) raised the company’s price target to $62, maintaining a Sector Outperform rating. Barclays (LON:BARC) also increased its price target to $58 and reiterated an Overweight rating, citing momentum in Twist Bioscience’s Express portfolio and Next-Generation Sequencing tools.
The company recently held its Annual Meeting of Stockholders, where stockholders approved an increase in authorized common stock by an additional 100 million shares and amendments to the company’s equity incentive plan. These changes include an increase of 3.7 million shares reserved for issuance and the removal of the "evergreen" provision. Furthermore, the company’s Charter was amended to provide for the exculpation of certain officers from liability under specific circumstances. Twist Bioscience’s strategic moves and financial performance have positioned it favorably among analysts, with a focus on profitability and disciplined investments in Biopharma and DNA Data Storage.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.